For patients diagnosed with Stage 3 melanoma, the end of surgery and immunotherapy is rarely the end of the anxiety. Even after aggressive treatment, the cancer returns in roughly half of all patients within five years. Now, a new approach using personalized mRNA technology is offering a potential way to change those odds.

New clinical trial results presented Monday at the American Society of Clinical Oncology’s annual meeting show that a custom-made mRNA vaccine, when paired with standard immunotherapy, cut the risk of melanoma recurrence by nearly 50 percent over a five-year period. The findings, published in the Journal of Clinical Oncology, suggest that training the immune system to hunt for specific tumor signatures may be the key to preventing relapse.

How the Vaccine Trains the Immune System

Surgery remains the primary defense against melanoma, but it is often unable to catch microscopic cancer cells that remain in the body. These lingering cells are the source of future recurrences. The experimental vaccine, developed by Moderna and Merck, is designed to act as a precision-guided search party for the immune system.

Researchers create each vaccine by analyzing the genetic material of a patient’s specific tumor. They identify unique DNA mutations that cause the cancer cells to display specific proteins, known as neoantigens. The vaccine is then programmed to carry information for up to 34 of these top neoantigens, effectively teaching the patient’s T-cells to recognize and destroy any cells carrying those specific markers.

"It’s training the immune system to recognize the tumor signature long after the tumor is gone," said Jeff Coller, a professor of RNA biology and therapeutics at Johns Hopkins University, who was not involved in the study.

The Five-Year Milestone

In the trial, 107 patients received the personalized vaccine alongside standard immunotherapy (pembrolizumab, or Keytruda), while a control group of 50 patients received only the standard immunotherapy. After five years, nearly 70 percent of those who received the vaccine remained cancer-free, compared to 49 percent in the standard treatment group.

Beyond just preventing recurrence, the vaccine also appeared to reduce the risk of the cancer metastasizing by nearly 60 percent. Because most melanoma recurrences occur within the first five years, these long-term results are particularly significant for clinicians who use this window to determine the intensity of patient monitoring.

What Experts Say

While the results are encouraging, the medical community is now looking toward a larger, phase 3 trial involving 1,000 patients across the U.S. and Europe to confirm these findings. Dr. Janice Mehnert, the senior trial investigator and director of the melanoma program at NYU Langone Health, noted that the current data provides a strong signal of efficacy.

One of the most notable aspects of the vaccine is its safety profile. Dr. Shailender Bhatia, director of the melanoma team at Fred Hutch Cancer Center, pointed out that adding new drugs to immunotherapy regimens often increases toxicity without necessarily improving outcomes. In this trial, however, patients reported side effects similar to those seen with mRNA Covid-19 vaccines—such as chills and headaches—which were generally manageable and short-lived.

"Generally what we have seen is that if we layer more drugs with immunotherapy, it causes more toxicity but not more benefit," Bhatia said. "So that is where the results of this trial are promising."

Key Takeaways

  • The personalized mRNA vaccine uses a patient's own tumor genetic material to teach the immune system to identify and kill lingering cancer cells.
  • In a trial of 157 patients, those who received the vaccine had a 70% cancer-free rate at five years, compared to 49% for those on standard treatment alone.
  • The vaccine showed a favorable safety profile, with side effects limited to mild, flu-like symptoms similar to those associated with mRNA Covid-19 vaccines.

This article is for informational purposes only. Always consult a qualified healthcare professional before making any medical decisions.